Highlights Newsletter 3

This newsletter presents you the following key sessions:

1. Podcast with prof. Romain Cohen about one year of nivolumab plus ipilimumab for MSI/dMMR metastatic
    colorectal cancer patients

2. Meaningful objective response rate with trastuzumab deruxtecan in HER2-associated advanced
    colorectal cancer

3. Combination of docetaxel, cisplatin and 5-FU as a new standard neoadjuvant treatment for oesophageal
    squamous cell cancer

4. STRIDE as a novel, first-line standard of care regimen for unresectable hepatocellular carcinoma

5. Perioperative immunotherapy instead of chemotherapy for patients with localised MSI/dMMR oeso-
    gastric adenocarcinoma